Health Connexions Introduces Serenium, a Revolutionary Approach to Predict and Pre-Empt Chronic Diseases like Diabetes, Heart Disease and Depression

Share Article

Serenium will disrupt and revolutionize the current approach to managing the burden of chronic disease by identifying at-risk individuals before they develop diseases like diabetes, heart disease or depression. With a simple urine test, Serenium will screen people to predict and pre-empt chronic disease with this first-ever set of clinically validated biomarkers.



Serenium will disrupt and revolutionize the current approach to managing the burden of chronic disease by identifying at-risk individuals before they develop diseases like diabetes, heart disease or depression.

Health Connexions is pleased to partner with Serenium to bring forward a one-of-a-kind, new method to improve human health on a global scale. Serenium has developed a revolutionary, first-ever set of clinically validated biomarkers – a screening tool to predict and pre-empt chronic disease. With a simple urine test, Serenium will disrupt and vastly improve the current medical paradigm by screening people to identify at-risk individuals before they develop chronic diseases.

The biomarkers developed by Serenium are estimated to be a billion dollar diagnostic solution worldwide, helping to combat costly and debilitating chronic diseases before they occur (diabetes, heart disease, depression). There are currently billions of people worldwide at risk for chronic disease. In the United States alone, chronic disease accounts for 86% of health care costs, with 50% of the adult population at risk or already battling a chronic disease. Serenium’s screening process will lead to significant savings for the 2 plus trillion dollars spent on healthcare every year in the US.

“We are thrilled to be able to help Serenium advance their biomarkers to the market,” says Dawn Van Dam, President and CEO of Health Connexions. “Just as we are making advances in combating infectious diseases on a global scale, chronic diseases are rising as humankind’s new and long-term challenge. Serenium’s revolutionary screening process allows us to impact and prevent these costly diseases that are debilitating millions of people each day.”

Serenium’s screening technology works by detecting biomarkers that are present in people with sleep apnea. A major symptom of sleep apnea is snoring. Sleep apnea is a condition that effects an estimated 23% of women and 49% of men, and it is tremendously underdiagnosed (up to 80%). Sleep apnea can cause interrupted breathing and snoring, that breaks the natural sleep rhythm, reducing the amount of deep, restorative sleep which is so important to a person’s health. Consequently, poor sleep represents the third pillar in health: diet, exercise and sleep.

Since sleep apnea also alters the immune system, it creates a cascade of negative health pathways that ultimately lead and contribute to chronic diseases. Indeed, people with sleep apnea are two to five times more likely to have a chronic disease. With Serenium’s biomarkers, we will be able to find those with sleep apnea early. Their physicians can then treat the sleep apnea and stop or slow the costly and personally debilitating progression toward these chronic diseases like diabetes, heart disease and depression.

Serenium’s screening technology is a quick and easy-to-use urine test that requires no hospital visits. It is being developed to be used in a physician’s office, or as a consumer home test. It is projected to cost under $50 per test, and it produces comparable results to the current gold standard for sleep apnea testing: in-clinic or in-hospital sleep lab testing (polysomnography or PSG).

“Sleep is becoming as clinically important to consumers’ health as nutrition and exercise. Early screening with Serenium’s biomarker-based urine test can identify risks and contribute to avoiding chronic diseases,” says Cory Zwerling, CEO and Chairman of Serenium. “If you know someone who snores, they may be at risk of sleep apnea and of developing any number of chronic diseases. We can empower people to pursue earlier screening with an easy-to-use, economical solution to predict and pre-empt costly and debilitating diseases like diabetes, heart disease and depression.”

Serenium is currently seeking funding and support for development and entry into the global market. For more information about the opportunity to provide capital, or to partner with Serenium to prepare to launch onto the world stage, contact their CEO, Cory Zwerling at coryz(at)sereniumscreen.(dot)com.

About Health Connexions
The Health Connexions™ vision is to transform science into commercial success. Health Connexions helps clients in the life sciences and health care sectors by leveraging its extensive network and unique collaborative model in consulting, market research, technology evaluations and marketing communications services. Health Connexions also provides strategic advisory services for capital raising to fund new innovations, new opportunities, and the growth of established organizations. Visit

About Serenium
Serenium is a new company with the mission to proactively screen all children and adults who snore, in order to predict and pre-empt chronic disease.

Serenium’s team consists of:

  • M. Cory Zwerling: Previously President of Bristol-Myers Squibb Medical Imaging and CEO of Zosano Pharma, a biotechnology company.
  • David Rosen: Technology and health care entrepreneur with experience globally; previously CEO of an IT company.
  • International, world renowned, leading clinicians and researchers: Pioneers and leading clinical researchers in the study of sleep disorders and its impact on the development of chronic diseases in children and adults.


Forward-Looking Statements
Statements contained in this announcement that are not statements of historical fact may be deemed to be forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements which may be made in this announcement or which are otherwise made by or on behalf of the Company.

Media Contact:

M. Cory Zwerling
Chief Executive Officer

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Cory Zwerling
+1 650-224-6446
Email >
Visit website